Clinical trial · Interventional
Efficacy and Safety of Microtransplantation for Advanced and Relapsed Solid Tumors
NCT07356856CI-TRIAL-00101324not yet recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, microtransplantation (MST) will be administrated to patients diagnosed with advanced / relapsed solid tumors to assess the therapeutic efficacy and safety of conventional chemotherapy in combination with MST for the treatment of advanced/relapsed solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced and Relapsed Solid Tumors | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MST | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- microtransplantation; MST
- description
- conventional chemotherapy with microtransplantation
- interventionNames
- Biological: MST
Primary outcomes (2)
- measure
- Treatment-Emergent Adverse Events
- timeFrame
- 1 month
- description
- Treatment related mortality
- measure
- time of hematopoietic recovery
- timeFrame
- 1 month
- description
- Absolute neutrophil count \>500/μL; Platelets ≥20,000/μL
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Patients are 18 to 90 years old, regardless of gender or race; * Advanced / relapsed solid tumors (small cell lung cancer, ovarian cancer, cervical cancer, gastric and colorectal cancer, sarcoma, head and neck tumor, etc.) are confirmed by clinical or histopathological diagnosis; * More than two kinds of tumors are allowed; * Karnofsky score ≥ 40, ECoG physical status ≤ 3; * There are measurable lesions; Exclusion Criteria: * The researchers considered patients who were not suitable to participate in this experiment； * Patients with mental disorders； * Patients who refuse to cooperate with the treatment；
References
Publications (0)
Data not yet available
No reference posted for this study.